These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY Front Immunol; 2018; 9():727. PubMed ID: 29910795 [TBL] [Abstract][Full Text] [Related]
10. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study. Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594 [TBL] [Abstract][Full Text] [Related]
11. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606 [TBL] [Abstract][Full Text] [Related]
12. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma. Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710 [TBL] [Abstract][Full Text] [Related]
13. Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma. Kim M; Park JE; Kim HS; Kim N; Park SY; Kim YH; Kim JH Eur Radiol; 2021 Aug; 31(8):6374-6383. PubMed ID: 33569615 [TBL] [Abstract][Full Text] [Related]
14. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation. Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531 [TBL] [Abstract][Full Text] [Related]
15. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma. Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133 [TBL] [Abstract][Full Text] [Related]
17. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients. Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813 [TBL] [Abstract][Full Text] [Related]
18. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Soike MH; McTyre ER; Shah N; Puchalski RB; Holmes JA; Paulsson AK; Miller LD; Cramer CK; Lesser GJ; Strowd RE; Hinson WH; Mott RT; Johnson AJ; Lo HW; Laxton AW; Tatter SB; Debinski W; Chan MD Neuroradiology; 2018 Oct; 60(10):1043-1051. PubMed ID: 30094640 [TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
20. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis. Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]